EyeGate downsizes proposed IPO

Ophthalmology company EyeGate Pharmaceuticals Inc. (Waltham, Mass.) amended terms for its proposed IPO on NASDAQ underwritten by Aegis Capital Corp. The company now plans to sell 1.4 million shares at $6-$8. At $7, EyeGate would raise $10 million and be valued at $48.1 million. EyeGate filed to raise up to $28.8 million in July. ...